Experimental Mouse Infection
Experimental Mouse Infection - Related Videos
05:53
Use of In vivo Imaging to Monitor the Progression of Experimental Mouse Cytomegalovirus Infection in Neonates
0 Views •
Cited by 6 •
2013
Human Cytomegalovirus (HCMV) infection of neonates represents an important cause of mental retardation, yet the molecular events leading to virus-induced pathogenesis are still poorly understood. To investigate the dynamics of brain infection, we adapted whole-animal in vivo imaging to perform time-course analysis of neonates infected with a luciferase-recombinant virus.
07:40
Introducing Experimental Agents into the Mouse
0 Views •
2023
Many investigations performed in mice (Mus musculus) require the administration of an experimental agent to the animal. For example, it may be of interest to test the efficacy of a specific therapy, to induce a pathologic condition, or to administer anesthesia or palliative care. In order to ensure safe and efficient delivery, it is important to consider a variety of factors prior to the administration of the treatment. This video, which reviews agent administration in the mouse, begins by...
09:01
Chronic Salmonella Infected Mouse Model
0 Views •
Cited by 12 •
2010
Establish a chronic bacterial infected mouse model with persistent Salmonella typhimurium colonization in intestine for 27 weeks.
10:12
Experimental Infection of Mice with the Parasitic Nematode Strongyloides ratti
0 Views •
Cited by 2 •
2025
Strongyloides ratti is a parasitic nematode that causes transient infections in laboratory mice, displaying tissue-migrating and intestinal life stages. Here, we present a protocol for the maintenance of the parasite cycle in rats and experimental infection of mice, including parasite quantification in the head, lung, and intestine.
02:45
Induction of Experimental Autoimmune Encephalomyelitis in a Mouse Model
0 Views •
2025
The video demonstrates the induction of experimental autoimmune encephalomyelitis in a mouse model by injecting a combination of myelin oligodendrocyte glycoproteins and inactivated Mycobacterium tuberculosis. The model enables researchers to study disease mechanisms and test therapeutic interventions.
FAQs
Controlled exposure creates a defined starting point for comparing host responses across groups. Investigators can then follow pathogen burden, dissemination, inflammatory signaling, tissue damage, and antibody or cellular immunity as linked outcomes. Relating these measurements shows whether an immune response is associated with containment, uncontrolled spread, or disease severity, rather than treating infection as a single endpoint.
Controls help distinguish effects caused by the pathogen or microbial product from changes associated with experimental conditions or baseline biology. They also provide the comparison needed to interpret altered pathogen burden, inflammatory signals, tissue injury, and immune responses. Without that reference, an observed difference cannot be confidently attributed to the infection model itself.
Investigators can examine innate and adaptive immunity as distinct but connected components by pairing inflammatory signaling and tissue-damage measurements with antibody or cellular immunity readouts. Comparing these outcomes across infection conditions helps identify which immune features are associated with pathogen containment or pathology. This organism-level view links molecular mechanisms to disease outcomes.
Measurements of pathogen burden and distribution show whether the host is containing the challenge or allowing it to spread. When combined with inflammatory signaling and tissue-damage data, these measurements help separate microbial expansion from immune-mediated pathology. The result is a more informative picture of how host responses influence disease progression and containment.
By comparing pathogen burden, tissue damage, inflammatory signaling, and antibody or cellular immunity between appropriately designed groups, investigators can determine whether an intervention changes infection or host response. The same framework supports diagnostic strategy evaluation by connecting measurable biological signals with disease outcomes. These studies therefore assess coordinated effects rather than relying on one immune marker.
A useful workflow connects the exposure condition with multiple outcome categories: pathogen burden and spread, inflammatory signaling, tissue damage, and antibody or cellular immunity. Appropriate controls establish the comparison, while monitoring these measures together reveals relationships between microbial behavior, immune activation, and disease. This integrated approach strengthens interpretation of organism-level findings.
Mouse results are informative but should not be treated as direct predictions of every outcome in other settings. Their value comes from connecting molecular immune processes with organism-level disease measurements under controlled conditions. Careful interpretation uses the model to clarify mechanisms, compare disease outcomes, and evaluate strategies while recognizing that findings require contextual judgment.